Dominick Colangelo Sells 17,500 Shares of Vericel Co. (NASDAQ:VCEL) Stock

Vericel Co. (NASDAQ:VCEL) CEO Dominick Colangelo sold 17,500 shares of the stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $41.38, for a total transaction of $724,150.00. Following the transaction, the chief executive officer now directly owns 220,937 shares in the company, valued at approximately $9,142,373.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Vericel Price Performance

Shares of VCEL stock traded up $0.99 on Friday, hitting $41.66. The stock had a trading volume of 250,030 shares, compared to its average volume of 430,068. The business has a 50 day moving average of $45.34 and a 200 day moving average of $46.81. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -4,067.00 and a beta of 1.67. Vericel Co. has a 12-month low of $32.28 and a 12-month high of $54.10.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($0.10) EPS for the quarter, meeting the consensus estimate of ($0.10). Vericel had a net margin of 0.37% and a return on equity of 0.35%. The company had revenue of $52.70 million during the quarter, compared to the consensus estimate of $52.59 million. During the same quarter in the prior year, the company posted ($0.11) earnings per share. The firm’s revenue for the quarter was up 14.8% on a year-over-year basis. As a group, research analysts expect that Vericel Co. will post 0.12 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

VCEL has been the topic of several research analyst reports. BTIG Research cut their target price on shares of Vericel from $56.00 to $55.00 and set a “buy” rating on the stock in a research note on Monday, July 15th. Stephens raised their price objective on shares of Vericel from $56.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective on the stock. Canaccord Genuity Group started coverage on shares of Vericel in a research note on Friday, August 9th. They issued a “buy” rating and a $57.00 price objective on the stock. Finally, HC Wainwright raised their price objective on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. One investment analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $57.71.

Institutional Trading of Vericel

A number of large investors have recently added to or reduced their stakes in VCEL. Vanguard Group Inc. increased its holdings in Vericel by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 3,374,093 shares of the biotechnology company’s stock worth $120,151,000 after buying an additional 48,514 shares during the last quarter. Los Angeles Capital Management LLC increased its stake in shares of Vericel by 2.5% in the first quarter. Los Angeles Capital Management LLC now owns 27,367 shares of the biotechnology company’s stock worth $1,424,000 after purchasing an additional 673 shares in the last quarter. Park Avenue Securities LLC purchased a new position in shares of Vericel in the first quarter worth about $262,000. Congress Asset Management Co. MA increased its stake in shares of Vericel by 509.1% in the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock worth $43,514,000 after purchasing an additional 699,147 shares in the last quarter. Finally, MCF Advisors LLC increased its stake in shares of Vericel by 86.1% in the first quarter. MCF Advisors LLC now owns 482 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 223 shares in the last quarter.

About Vericel

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.